OsteoarthritisPhase 3NCT00809354
Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip
A Phase 3 study testing NSAID and tanezumab in people with Osteoarthritis and Arthritis, run by Pfizer at 333 sites in 12 countries.
Trial summary
The purpose of this study is to investigate the long-term analgesic efficacy and safety of tanezumab for patients with osteoarthritis (OA) of the knee or hip currently experiencing partial benefit from, and are tolerating, non-steroidal anti-inflammatory drug (NSAID) therapy. Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Osteoarthritis, Arthritis
- What is being tested?
- NSAID and tanezumab
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 2,720 participants
- Where
- 333 sitesin 12 countries
- Study dates
- 12 Feb 2009to 12 Jan 2011
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Osteoarthritis of the knee or hip according to ACR criteria with Kellgren-Lawrence x-ray grade equal to, or greater than, 2.
- Patients must be experiencing some benefit from their current stable dose regimen of oral NSAID therapy of either naproxen 500-1000 mg/day or celecoxib 200 mg/day (either 100 mg BID or 200 mg QD) and be tolerating their NSAID regimen.
- Pain level and function levels as required by the protocol at Screening and Baseline.
- Willing to discontinue all non-study pain medications for osteoarthritis except rescue medication (acetaminophen) and not use prohibited pain medications throughout the duration of the study except as permitted per protocol.
- Willing and able to comply with lifestyle guidelines, scheduled visits, treatment plan, laboratory tests and other study procedures.
Who cannot join
- Pregnant women.
- BMI greater than 39.
- Fibromyalgia, regional pain caused by lumbar or cervical compression with radiculopathy or other moderate to sever pain that may confound assessments or self-evaluation of the pain associated with OA.
- Signs and symptoms of clinically significant cardiac disease with 6 months prior to screening.
- Diagnosis of TIA within 6 months prior to screening or diagnosis of stroke with residual deficits that would preclude completion of required study activities.
- History, diagnosis, signs or symptoms of clinically significant neurological and/or psychiatric disease/disorder.
Show all 9Show fewer
- At Screening: uncontrolled hypertension, hemoglobin A1c greater than or equal to 10%, ALT or AST greater than or equal to 3X upper limit of normal, creatinine exceeding 1.7 mg/dL (men) or 1.5 mg/dL (women).
- Patients on warfarin or other coumadin anticoagulant therapy and/or lithium therapy within 30 days prior to screening.
- Known hypersensitivity to NSAIDs or cyclooxygenase inhibitors.
Trial locations and contacts
333 sites in 12 countries.
333 sites in 12 countries
United States250 sites
Abilene Arthritis Center
Abilene, Texas, 79601
Daystar Clinical Research, Inc.
Akron, Ohio, 44313
The Center for Rheumatology, LLP
Albany, New York, 12206
Blair Orthopedics Associates
Altoona, Pennsylvania, 16602
Advanced Clinical Research Institute
Anaheim, California, 92801
Orange County Clinical Trials, Inc.
Anaheim, California, 92801
Perimeter Institute for Clinical Reseach, Inc.
Atlanta, Georgia, 30338
Laureate Clinical Research Group
Atlanta, Georgia, 30342
Tekton Research, Inc.
Austin, Texas, 78745
Dr. Paul K. Pickrell (Physician's Office)
Austin, Texas, 78746
Arthritis and Rheumatic Disease Specialties
Aventura, Florida, 33180
International Physicans Research
Aventura, Florida, 33180
Surgery Center of Aventura
Aventura, Florida, 33180
American Health Network of Indiana, LLC
Avon, Indiana, 46123
Gulf Coast Research, LLC
Baton Rouge, Louisiana, 70808
The Bone and Joint Clinic
Baton Rouge, Louisiana, 70808
Northwest Clinical Research Center
Bellevue, Washington, 98007
Bend Memorial Clinic
Bend, Oregon, 97701
Bend Memorial Clinic
Bend, Oregon, 97702
The Center for Clinical Trials
Biloxi, Mississippi, 39531
Quest Research Institute
Bingham Farms, Michigan, 48025
Rheumatology Associates, P.C.
Birmingham, Alabama, 35205
Radiant Research
Birmingham, Alabama, 35209
Alliance Clinical Research
Birmingham, Alabama, 35215
Shades Mountain Imaging
Birmingham, Alabama, 35216
HeartCare
Bradenton, Florida, 34202
Joao MA Nascimento, MD
Bridgeport, Connecticut, 06606
Beacon Clinical Research
Brockton, Massachusetts, 02301
Arthritis and Osteoporosis Associates of Brooklyn Heights
Brooklyn, New York, 11201
Med Center
Carmichael, California, 95608
Radiant Research - Phoenix Southeast
Chandler, Arizona, 85225
Rehabilitation Institute of Chicago
Chicago, Illinois, 60611
eStudySite
Chula Vista, California, 91911
New Horizons Clinical Research
Cincinnati, Ohio, 45242
Doctor's Urgent Care Offices
Cincinnati, Ohio, 45246
Sterling Research Group
Cincinnati, Ohio, 45246
Clinical Research of West Florida, Inc.
Clearwater, Florida, 33765
The Family Healthcare Center, PA
Clinton, South Carolina, 29325
Colorado Springs Family Practice
Colorado Springs, Colorado, 80909
Lynn Institute of the Rockies
Colorado Springs, Colorado, 80909
Columbia Arthritis Center P.A.
Columbia, South Carolina, 29204
Southern Orthopaedic Sports Medicine
Columbia, South Carolina, 29204
Columbus Clinical Research, Inc.
Columbus, Ohio, 43213
Optimed Research, LTD
Columbus, Ohio, 43235
Nature Coast Clinical Research
Crystal River, Florida, 34429
Homestead Clinical Research Group, P.A.
Cutler Bay, Florida, 33189
Metroplex Clinical Research Center
Dallas, Texas, 75231
STAT Research, Inc.
Dayton, Ohio, 45408
Dayton Science Institute (DSI)
Dayton, Ohio, 45415
Hometown Urgent Care and Research
Dayton, Ohio, 45432
PHP - Center for Clinical Research
Dayton, Ohio, 45439
Covance CRU, Inc.
Daytona Beach, Florida, 32117
Robert W. Levin MD
Dunedin, Florida, 34698
Anderson and Collins Clinical Research Inc.
Edison, New Jersey, 08817
Central Jersey Medical Research Center
Elizabeth, New Jersey, 07202
Center for Arthritis and Osteoporosis
Elizabethtown, Kentucky, 42701
Colorado Arthritis Center, PC
Englewood, Colorado, 80113
MediSphere Medical Research Center, LLC
Evansville, Indiana, 47714
Med Investigations, Inc.
Fair Oaks, California, 95628
Internal Medicine Associates
Fargo, North Dakota, 58103
Lillestol Research, LLC
Fargo, North Dakota, 58103
No. County Internal Medicine & Rheumatology
Florissant, Missouri, 63031
Internal Medicine Associates
Fort Myers, Florida, 33912
Clinical Physiology Associates, Clinical Study Center
Fort Myers, Florida, 33916
Arthritis & Osteoporosis Associates, P.A.
Freehold, New Jersey, 07728
Dedicated Clinical Research
Goodyear, Arizona, 85395
Eclipse Clinical Research
Green Valley, Arizona, 85614
Physicians East P. A.
Greenville, North Carolina, 27834
Physicians East, PA
Greenville, North Carolina, 27834
Radiant Research Inc
Greer, South Carolina, 29651
Mark Fisher, MD, FACRUC
Haddon Heights, New Jersey, 08035
Research Consultants Group
Hialeah, Florida, 33010
Palm Springs Research Institute
Hialeah, Florida, 33012
Clinical Trials of America, Inc
Hickory, North Carolina, 28601
Piedmont Rheumatology
Hickory, North Carolina, 28602
Peters Medical Research
High Point, North Carolina, 27262
East-West Medical Research Institute
Honolulu, Hawaii, 96814
One Step Diagnostic
Houston, Texas, 77030
Accurate Clinical Research
Houston, Texas, 77034
Miracle Medical Center
Houston, Texas, 77055
DM Clinical Research
Houston, Texas, 77070
Rheumatology Associates of North Alabama, PC
Huntsville, Alabama, 35801
Saadat Ansari, MD Office
Huntsville, Alabama, 35801
Institute of Arthritis Research
Idaho Falls, Idaho, 83404
Arthritis Clinic
Jackson, Tennessee, 38305
Jacksonville Center for Clinical Research
Jacksonville, Florida, 32216
Rheumatology PC
Kalamazoo, Michigan, 49009
Dynamic Clinical Research, Inc.
Kansas City, Missouri, 64114
Joan Prouty Moore
Kansas City, Missouri, 64114
Orthopaedic & Occupational Medicine
Kansas City, Missouri, 64114
Triwest Research
La Mesa, California, 91942
Midwest Internal Medicine, PLLC
Lake Havasu City, Arizona, 86403
Florida Arthritis
Lake Mary, Florida, 32746
Lakewood Orthopedic Medical & Surgical Group
Lakewood, California, 90712
Premier Clinical Research LLC.
Lakewood, California, 90712
Justus J Fiechtner, MD
Lansing, Michigan, 48910-8595
PCM Medical Services
Lansing, Michigan, 48917
Rheumatology Consultants of Delaware/Delaware Arthritis
Lewes, Delaware, 19958
Pain Treatment Center of the Bluegrass
Lexington, Kentucky, 40503
Pasadena Pharmacy
Lexington, Kentucky, 40503
Physician Research Collaboration, LLC
Lincoln, Nebraska, 68516
Little Rock Diagnostic Clinic, PA
Little Rock, Arkansas, 72205
Little Rock Family Practice Clinic
Little Rock, Arkansas, 72205
Prohealth Partners
Long Beach, California, 90808
Peak Health Medical Group, Inc.
Los Angeles, California, 90025
Gill Orthopedic Center
Lubbock, Texas, 79410
Robert R. King, M.D.
Lubbock, Texas, 79410
Commonwealth Biomedical Research, LLC
Madisonville, Kentucky, 42431
Multicare Specialists
Madisonville, Kentucky, 42431
David R. Mandel, MD, Inc
Mayfield, Ohio, 44143
Ramesh C. Gupta, M.D.
Memphis, Tennessee, 38119
Idaho Arthritis & Osteoporosis Center, PC
Meridian, Idaho, 83642-6356
Arizona Arthritis & Rheumatology Associates, P.C.
Mesa, Arizona, 85202
Pivotal Research Centers
Mesa, Arizona, 85210
Southwest Rheumatology, PA
Mesquite, Texas, 75150
Pharmax Research Clinic, Inc.
Miami, Florida, 33126
Community Research Foundation
Miami, Florida, 33155
International Research Associates, LLC
Miami, Florida, 33183
Southwest Rheumatology and Research Group, LLC
Middleburg Heights, Ohio, 44130
Pivotal Research Centers
Midvale, Utah, 84047
Coastal Clinical Research, Inc.
Mobile, Alabama, 36608
Office of Vaughn H. Mancha, Jr., MD
Montgomery, Alabama, 36117
Saltzer Medical Group PA
Nampa, Idaho, 83686
Jeffrey Alper MD Research
Naples, Florida, 34102
Synergy Clinical Research Center
National City, California, 91950
Hill Country Medical Associates
New Braunfels, Texas, 78130
Neurology Clinic of Central Texas
New Braunfels, Texas, 78130
NYU Hospital for Joint Diseases
New York, New York, 10003
Integris Family Care of Norman
Norman, Oklahoma, 73069
LION Research
Norman, Oklahoma, 73069
Central Sooner Research
Norman, Oklahoma, 73071
Elise Wiesner, MD
Norman, Oklahoma, 73071
McBride Clinic, Inc
Norman, Oklahoma, 73072
McBride Clinic
Norman, Oklahoma, 73072
American Family Medicine
Ocala, Florida, 34471
Renstar Medical Research
Ocala, Florida, 34471
eStudySite
Oceanside, California, 92056
McBride Clinic, Inc
Oklahoma City, Oklahoma, 73013
Bone and Joint Hospital at St. Anthony
Oklahoma City, Oklahoma, 73103
Christine Codding, MD
Oklahoma City, Oklahoma, 73103
Health Research of Oklahoma
Oklahoma City, Oklahoma, 73103
Mc Bride Clinic
Oklahoma City, Oklahoma, 73103
Lynn Health Science Institute
Oklahoma City, Oklahoma, 73112
Associated Orthopedics, Inc.
Oklahoma City, Oklahoma, 73119
Hillcrest Clinical Research
Oklahoma City, Oklahoma, 73119
Olive Branch Family Medical Center
Olive Branch, Mississippi, 38654
Westroads Medical Group
Omaha, Nebraska, 68114
Gundersen Clinic Ltd.
Onalaska, Wisconsin, 54650
Sunshine Research Center
Opa-locka, Florida, 33054-3818
Arthritis Associates
Orlando, Florida, 32804
Vince and Associates Clinical Research
Overland Park, Kansas, 66211
Vince and Associates Clinical Research
Overland Park, Kansas, 66212
MD Medical Research
Oxon Hill, Maryland, 20745
Arthritis Research of Florida, Inc.
Palm Harbor, Florida, 34684
Desert Medical Group Inc., Desert Oasis Healthcare
Palm Springs, California, 92262
Arizona Arthritis & Rheumatology Research, PLLC
Paradise Valley, Arizona, 85253
Philip Blum
Pasadena, Texas, 77504
New Jersey Physicians, LLC
Passaic, New Jersey, 07055
Pearland Primary Care Associates
Pearland, Texas, 77584
Southwest Clinical Research Centers, LLC
Pearland, Texas, 77584
University Clinical Research
Pembroke Pines, Florida, 33024
Pembroke Clinical Trials
Pemkbroke Pines, Florida, 33028
Pivotal Research Centers
Peoria, Arizona, 85381
Elite Clinical Studies, LLC
Phoenix, Arizona, 85018
Arizona Arthritis & Rheumatology Associates, P.C.
Phoenix, Arizona, 85037
Highland Community Hospital
Picayune, Mississippi, 39466
Mississippi Medical Research
Picayune, Mississippi, 39466
Advent Clinical Research Center Inc
Pinellas Park, Florida, 33781
Advent Clinical Research Centers
Pinellas Park, Florida, 33781
Clinical Trials Research Services, LLC
Pittsburgh, Pennsylvania, 15206
Berkshire Rheumatology
Pittsfield, Massachusetts, 01201
Prem C. Chatpar, MD, LLC
Plainview, New York, 11803
Plano Primary Care Clinic
Plano, Texas, 75075
Advanced Family Medical Care
Plano, Texas, 75093
Berma Research Group
Plantation, Florida, 33324
Accord Clinical Research, LLC
Port Orange, Florida, 32129
Doris M. Rice, M.D., F.A.C.R.
Portsmouth, Virginia, 23701
Wake Internal Medicine Consultants Inc
Raleigh, North Carolina, 27612
Wake Research Associates
Raleigh, North Carolina, 27612
Advances in Medicine
Rancho Mirage, California, 92270
Regional Health Clinical Research
Rapid City, South Dakota, 57701
Regional Medical Clinical-Rheumatology
Rapid City, South Dakota, 57701
National Clinical Research Richmond Inc.
Richmond, Virginia, 23294
Hypothe Test, LLC
Roanoke, Virginia, 24018
The Carolina Center for Rheumatology and Arthritis Care, PA
Rock Hill, South Carolina, 29732
Rockford Orthopedic Associates
Rockford, Illinois, 61107
ACCR/Internal Medicine
Roswell, Georgia, 30075
Mercy Imaging Center
Sacramento, California, 95823
Northern Clinical Research
Sacramento, California, 95831
Crescent Medical Research
Salisbury, North Carolina, 28144
Optimum Clinical Research, Inc.
Salt Lake City, Utah, 84102
Radiant Research, Inc.
Salt Lake City, Utah, 84107
Alamo Clinical Research Associates
San Antonio, Texas, 78212
Alamo Clinical Research Consultants
San Antonio, Texas, 78212
Texas Arthritis Research Center, PA
San Antonio, Texas, 78217
Clinical Trials of Texas, Inc.
San Antonio, Texas, 78229
Innovative Clinical Trials
San Antonio, Texas, 78229
Radiant Research San Antonio
San Antonio, Texas, 78229
SAM Clinical Research Center
San Antonio, Texas, 78229
San Antonio Preventive & Diagnostic Medicine, PA
San Antonio, Texas, 78229
South Texas Radiology Imaging Center
San Antonio, Texas, 78229
The Rehab Group
San Antonio, Texas, 78229
California Research Foundation
San Diego, California, 92103-6204
San Diego Arthritis Medical Clinic
San Diego, California, 92108
Kaiser Permanente Medical Center
San Francisco, California, 94118
eStudySite
San Jose, California, 95124
Trinity Clinical Trials
Santa Ana, California, 92701
Apex Research Institute
Santa Ana, California, 92705
HeartCare Research
Sarasota, Florida, 34232
Kennedy-White Orthopaedic Center
Sarasota, Florida, 34232
Sarasota Center for Clinical Research
Sarasota, Florida, 34232
Lovelace Scientific Resources
Sarasota, Florida, 34233
The Arthritis Specialty Centre
Sarasota, Florida, 34233
Cochise Clinical Research
Sierra Vista, Arizona, 85635
Springfield Clinic
Springfield, Illinois, 62702
Springfield Clinical Research Department
Springfield, Illinois, 62703
Medex Healthcare Research, Inc.
St Louis, Missouri, 63117
Rheumatology and Internal Medicine Associates of West County, P.C.
St Louis, Missouri, 63131
A & A Pain Institute
St Louis, Missouri, 63141
Arthritis Consultants Inc.
St Louis, Missouri, 63141
Dale G. Bramlet, MD, P.L.
St. Petersburg, Florida, 33713
St. Joseph Medical Associates
Stockton, California, 95204
Sugar Land Med-Ped, PA
Sugar Land, Texas, 77479
Tacoma Center for Arthritis Research, PS
Tacoma, Washington, 98405-2308
Soutwest Florida Clinical Research Center
Tampa, Florida, 33609-3018
Stedman Clinical Trials
Tampa, Florida, 33613
Tampa Medical Group, PA
Tampa, Florida, 33614
Rheumatology Associates of North Jersey
Teaneck, New Jersey, 07666
Premiere Phamaceutical Research, LLC
Tempe, Arizona, 85282
Scott & White Healthcare
Temple, Texas, 76508
SPRI Bronx LLC
The Bronx, New York, 10454
Martin Diagnostic Clinic
Tomball, Texas, 77375
Arthritis & Osteoporosis Associates
Toms River, New Jersey, 08757
Medical Research Associates
Traverse City, Michigan, 49684
Premier Research
Trenton, New Jersey, 08611
New England Research Associates, LLC
Trumbull, Connecticut, 06611
Radiant Research
Tucson, Arizona, 85710
Arizona Research Associates
Tucson, Arizona, 85712-2142
Quality of Life Medical and Research Center
Tucson, Arizona, 85712
Tucson Orthopaedic Institute
Tucson, Arizona, 85712
Rheumatology Associates Inc
Tulsa, Oklahoma, 74136
Deerbrook Medical Associates
Vernon Hills, Illinois, 60061
Arthritis, Rheumatic & Back Disease Associates
Voorhees Township, New Jersey, 08043
Omega Medical Research
Warwick, Rhode Island, 02886
MedVadis Research Corporation
Watertown, Massachusetts, 02472
Integrated Clinical Trial Services, Inc
West Des Moines, Iowa, 50265
Southgate Medical Group
West Seneca, New York, 14224
Westlake Medical Center
Westlake Village, California, 91361
Aquilo Clinical Research
Yukon, Oklahoma, 73099
Florida Medical Clinic, PA
Zephyrhills, Florida, 33542
South Africa14 sites
Tiervlei Trial Center
Bellville
Worthwhile Clinical Trials
Benoni, 1500
Josha Research
Bloemfontein, 9301
Vincent Pallotti Hospital
Cape Town, 7405
Private Practice
Durban, 4091
Randles Road Medical Center
Durban, 4091
A. Briel
Durbanville, 7550
Origin Clinical Research
Johannesburg, 2060
Clinresco Centres (Pty) Ltd
Kempton Park, 1619
Phelang Private Hospital Research Unit
Mamelodi East, Pretoria, 0122
Paarl Research Center
Paarl, 7646
136 Panorama Medical Center
Panorama, CAPE TOWN, 7500
TREAD Research
Parrowvalley, 7500
Clinical Research Unit
Pretoria, 0083
Canada12 sites
MAC Research Inc.
Hamilton, Ontario, L8N 2B6
KW Musculoskeletal Research Inc.
Kitchener, Ontario, N2M 5N6
Office of Diane Wilson
Lunenburg, Nova Scotia, B0J 2C0
The Arthritis Program Research Group
Newmarket, Ontario, L3Y 3R7
SKDS Research Inc.
Newmarket, Ontario, L3Y 5G8
Groupe de Recherche en Rhumatologie et Maladies Osseuses
Québec, Quebec, G1V 3M7
Clinique Medicale St-Louis
Québec, Quebec, G1W 4R4
Polyclinique St. Eustache
Saint-Eustache, Quebec, J7P 4J2
Diex Research Sherbrooke Inc.
Sherbrooke, Quebec, J1H 1Z1
Dr. Saeed Shaikh
St. Catharines, Ontario, L2N 7E4
Dr. Anil Gupta
Toronto, Ontario, M9V 4B4
Centre de Recherche Musculo-Squelettique
Trois-Rivières, Quebec, G8Z 1Y2
Spain9 sites
Complejo Hospitalario Universitario de A Coruna
A Coruña, 15006
Hospital de Cruces, Servicio de Reumatologia
Barakaldo (Vizcaya), 48903
Clinica CIMA
Barcelona, 08034
Servicio de Reumatologia,Institut Ferran de Reumatologia-Clinica CIMA
Barcelona, 08034
Hospital El Tomillar
Dos Hermanas, Sevilla, 41700
Hospital Universitario La Paz, Servicio de Reumatologia
Madrid, 28046
Corporacio Sanitaria Parc Tauli de Sabadell, Servicio de Reumatologia
Sabadell, Barcelona, 08208
Hospital Nuestra Senora de la Esperanza, Servicio de Reumatologia
Santiago de Compostela, A Coruna, 15705
Hospital Nuestra Senora de Valme, Servicio de Reumatologia
Seville, 41014
India8 sites
St. Johns Medical College Hospital, Department of Orthopaedics
Bangalore, Karnataka, 560034
M.S. Ramaiah Memorial Hospital, Department of Orthopaedics
Bangalore, Karnataka, 560054
ChanRe Rheumatology & Immunology Center & Research
Bangalore, Karnataka, 560079
PSG Institute of Medical Sciences and Research
Coimbatore, Tamil Nadu, 641004
CSM Medical University, Department of Rheumatology
Lucknow, Uttar Pradesh, 226018
KMC Hospital, Department of Orthopaedics
Mangalore, Karnataka, 575 001
Sancheti Hospital
Pune, Maharashtra, 411 005
Krishna Institute of Medical Sciences Ltd., Department of Rheumatology
Secunderabad, Andhra Pradesh, 500003
Philippines8 sites
Cebu Orthopedic Institute
Cebu City, 6000
Chong Hua Hospital, Medical Arts Center
Cebu City, 6000
Diaz Building
Cebu City, 6000
Asian Hospital and Medical Center
City of Muntinlupa, 1780
Davao Doctors Hospital, Medical Tower
Davao City, 8000
Davao Doctors Hospital
Davao City, 8000
Rayuma Clinic, OPD , Jose Reyes Memorial Medical Center
Manila, 1003
Chinese General Hospital and Medical Center, Out Patient Department
Manila
Ukraine8 sites
Chernivtsi Regional Clinical Hospital
Chernivtsi, 58002
City Clinical Hospital #5
Donetsk, 83000
V.K. Gusak Institute of Urgent and Recovery Surgery
Donetsk, 83045
Kiev City Oleksandrivska Clinical Hospital
Kiev, 01601
Kiev City Clinical Hospital #3
Kiev, 02125
State Institution "Research Centre for Radiation Medicine AMS of Ukraine"
Kiev, 03115
State Institution "Institute of Gerontology AMS of Ukraine"
Kiev, 04114
Municipal institution :Zaporizhzhya Regional Clinical Hospital
Zaporizhzhya, 69600
Russia6 sites
State Healthcare Institution Moscow City Clinical Hospital #4
Moscow, 115093
State Healthcare Institution: Moscow City Clinical Hospital #7
Moscow, 115446
Institution Of Russian Academy of Medical Sciences
Moscow, 115522
Federal State Healthcare Institution Clinical Hospital #122 n.a.Sokolov
Saint Petersburg, 194291
Saint-Petersburg State Healthcare Institution "City Hospital #26"
Saint Petersburg, 196247
Saint Petersburg State Medical University named after Pavlov
Saint Petersburg, 197022
Colombia5 sites
Centro Integral de Reumatologia e Inmunologia CIREI
Bogota, Cundinamarca
Riesgo de Fractura S.A.
Bogota-Cundinamarca
Hospital Pablo Tobon Uribe
Medellín, Antioquia
Clinica Las Americas
Medellín
Reumatologya S.A.
Medellín
Mexico5 sites
Unidad de Enfermedades Reumaticas y Cronico Degenerativas S.C.
Coahuila, 27000
Hospital General de Culiacan, S.S., "Dr. Bernardo Gastelum".
Culiacan Sinaloa, CP 80230
URHIA(Unidad de Investigacion en Reumatologia)Hospital Civil de Guadalajara"Fray Antonio Alcalde"
Guadalajara, Jalisco, CP 44280
Hospital Aranda de la Parra
Leon Gto, C.P. 37000
Beneficencia Espanola de la Laguna
Torreon Coahuila, CP 27000
South Korea5 sites
Kyungpook National University Hospital
Daegu, 700-721
Inha University Hospital
Incheon, 400-711
Seoul National University Hospital
Seoul, 110-744
Hanyang University Hospital
Seoul, 133-792
The Catholic University of Korea, Seoul St.Mary's Hospital
Seoul, 137-701
Netherlands3 sites
READE
Amsterdam, 1056 AB
UMC St. Radboud
Nijmegen, 6525 GA
UMC Utrecht
Utrecht, 3584 CX
About this study
Official title: A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF THE LONG-TERM ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ALONE OR IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) VERSUS NSAIDS ALONE IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
The purpose of this study is to investigate the long-term analgesic efficacy and safety of tanezumab for patients with osteoarthritis (OA) of the knee or hip currently experiencing partial benefit from, and are tolerating, non-steroidal anti-inflammatory drug (NSAID) therapy.
Read the detailed description
This study was terminated on 28 October 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
- Conditions
- Osteoarthritis, Arthritis
- Being tested
- NSAID, tanezumab
- Keywords
- monoclonal antibody, nerve growth factor (NGF), anti-NGF, tanezumab, PF-04383119, RN624, osteoarthritis (OA)
- Medical subject headings
- Osteoarthritis, Arthritis, Hereditary Sensory and Autonomic Neuropathies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NSAIDDrug
IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
tanezumabBiological
IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56
tanezumabBiological
IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56
tanezumabBiological
IV tanezumab 5 mg every 8 weeks (through Week 48)
NSAIDDrug
Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
tanezumabBiological
IV tanezumab 10 mg every 8 weeks (through Week 48)
NSAIDDrug
Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
| Study group | Role | What they receive |
|---|---|---|
| IV Placebo + NSAID | Active comparator | Oral NSAID Receives: Drug: NSAID |
| Tanezumab 5 mg | Experimental | IV tanezumab 5 mg every 8 weeks (through Week 48) Receives: Biological: tanezumab |
| Tanezumab 10 mg | Experimental | IV tanezumab 10 mg every 8 weeks (through Week 48) Receives: Biological: tanezumab |
| Tanezumab 5 mg + NSAID | Experimental | IV doses of tanezumab 5 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks Receives: Biological: tanezumab; Drug: NSAID |
| Tanezumab 10 mg + NSAID | Experimental | IV doses of tanezumab 10 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks Receives: Biological: tanezumab; Drug: NSAID |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.
Measured: Baseline, Week 16
Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip).The WOMAC physical function subscale was comprised of 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Total score range for WOMAC physical function subscale score was 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Physical function refers to participant's ability to move around and perform usual activities of daily living.
Measured: Baseline, Week 16
Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Week 16
Patient global assessment of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition.
Measured: Baseline, Week 16
Secondary outcomes (44)
Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.
Measured: Baseline, Weeks 2, 4, 8, 12, and 24
Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip).The WOMAC physical function subscale was comprised of 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Total score range for WOMAC physical function subscale score was 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Physical function refers to participant's ability to move around and perform usual activities of daily living.
Measured: Baseline, Weeks 2, 4, 8, 12, and 24
Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip).The WOMAC physical function subscale was comprised of 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Total score range for WOMAC physical function subscale score was 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Physical function refers to participant's ability to move around and perform usual activities of daily living.
Measured: Baseline, Weeks 2, 4, 8, 12, 24, 32, 40, 48, and 56
Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)
Patient global assessment of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= mild symptoms and no limitation of normal activities, 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (Very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition.
Measured: Baseline, Weeks 2, 4, 8, 12, and 24
Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)
Patient global assessment of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= mild symptoms and no limitation of normal activities, 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (Very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response: Baseline Observation Carried Forward (BOCF)
Participants were considered as OMERACT-OARSI responder: if the improvement from baseline to week of interest was greater than or equal to (>=) 50 percent and >=2 units in WOMAC pain subscale or WOMAC physical function subscale score, or at least 2 of the following 3 being true: improvement from baseline to week of interest was >=20 percent and >=1 unit in 1) WOMAC pain subscale score, 2) WOMAC physical function subscale score, 3) PGA of osteoarthritis. WOMAC pain subscale assess amount of pain experienced (score: 0 [no pain] to 10 [worst possible pain], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 [minimum difficulty] to 10 [maximum difficulty], higher score = worse physical function) and PGA of osteoarthritis (score: 1 [very good] to 5 [very poor], higher score = worse condition).
Measured: Weeks 2, 4, 8, 12, 16, and 24
Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response: Last Observation Carried Forward (LOCF)
Participants were considered as OMERACT-OARSI responder: if the improvement from baseline to week of interest was >=50 percent and >=2 units in WOMAC pain subscale or WOMAC physical function subscale score, or at least 2 of the following 3 being true: improvement from baseline to week of interest was >=20 percent and >=1 unit in 1) WOMAC pain subscale score, 2) WOMAC physical function subscale score, 3) PGA of osteoarthritis. WOMAC pain subscale assess amount of pain experienced (score: 0 [no pain] to 10 [worst possible pain], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 [minimum difficulty] to 10 [maximum difficulty], higher score = worse physical function) and PGA of osteoarthritis (score: 1 [very good] to 5 [very poor], higher score = worse condition).
Measured: Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Percentage of Participants With at Least 30 Percent (%), 50%, 70% and 90% Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score From Baseline at Weeks 2, 4, 8, 12, 16, and 24: BOCF
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis in index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Percentage of participants who experienced an improvement (reduction) of >=30%, >=50%, >=70%, or >=90% in the WOMAC pain subscale scores from Baseline were reported.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, and 24
Percentage of Participants With at Least 30%, 50%, 70% and 90% Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF)
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Percentage of participants who experienced an improvement (reduction) of >=30 percent, >=50%, >=70%, or >=90% in the WOMAC pain subscale scores from Baseline were reported.
Measured: Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Baseline Observation Carried Forward (BOCF)
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Number of participants who experienced reduction (as percent) of >0% to >=100% from Baseline in WOMAC pain subscale scores at Week 16 were reported.
Measured: Baseline, Week 16
Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF)
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Number of participants who experienced reduction (as percent) of >0% to >=100% from Baseline in WOMAC pain subscale scores at Week 16 were reported.
Measured: Baseline, Week 16
Percentage of Participants With Improvement of At Least 2 Points in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, 16, and 24: Baseline Observation Carried Forward (BOCF)
Patient global assessment of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= mild symptoms and no limitation of normal activities, 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (Very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition. Improvement signifies a decrease of at least 2 points on the 5-point scale relative to baseline value. Percentage of participants who showed an improvement of >=2 points on scale were reported.
Measured: Weeks 2, 4, 8, 12, 16, and 24
Percentage of Participants With Improvement of Atleast 2 Points in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56: Last Observation Carried Forward (LOCF)
Patient global assessment of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= mild symptoms and no limitation of normal activities, 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (Very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition. Improvement signifies a decrease of at least 2 points on the 5-point scale relative to baseline value. Percentage of participants who showed an improvement of >=2 points on scale were reported.
Measured: Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC stiffness subscale was a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis of the index joint (knee or hip) during the past 48 hours. Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip). It was calculated as mean of the scores from 2 individual questions scored on NRS of 0 (no stiffness) to 10 (worst stiffness), with higher scores indicate more stiffness. Total score range for WOMAC stiffness subscale score was 0 (no stiffness) to 10 (worst stiffness), where higher scores indicated more stiffness.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, and 24
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC stiffness subscale was a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in the index joint (knee or hip) during the past 48 hours. Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip). It was calculated as mean of the scores from 2 individual questions scored on NRS of 0 (no stiffness) to 10 (worst stiffness), with higher scores indicate more stiffness. Total score range for WOMAC stiffness subscale score was 0 (no stiffness) to 10 (worst stiffness), where higher scores indicated more stiffness.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). Each item is scored on a 0 to 10 NRS scale, where higher scores indicate higher pain/stiffness or worse function. WOMAC average score was calculated as the mean of 3 WOMAC subscale scores (pain, physical function and stiffness). Total score range was 0 (no response) to 10 (worse response), where higher score indicated worse response.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, and 24
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). Each item is scored on a 0 to 10 NRS scale, where higher scores indicate higher pain/stiffness or worse function. WOMAC average score was calculated as the mean of 3 WOMAC subscale scores (pain, physical function and stiffness). Total score range was 0 (no response) to 10 (worse response), where higher score indicated worse response.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis in index joint (knee or hip). Participants responded about the amount of pain they experienced when walking on a flat surface by answering the question: "How much pain have you had when walking on a flat surface?". Participants responded by using a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, and 24
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis in index joint (knee or hip). Participants responded about the amount of pain they experienced when walking on a flat surface by answering the question: "How much pain have you had when walking on a flat surface?". Participants responded by using a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Down Stairs at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). Participants responded about the amount of pain they experienced when going up or down stairs by answering the question: "How much pain have you had when going up or down the stairs?" Participants responded by using a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, and 24
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Down Stairs at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). Participants responded about the amount of pain they experienced when going up or down stairs by answering the question: "How much pain have you had when going up or down the stairs?" Participants responded by using a NRS of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24: Baseline Observation Carried Forward (BOCF)
The SF-36 health survey is a self-administered questionnaire that measures each of the following 8 health domains: domain 1= general health, domain 2= physical function, domain 3= role physical, domain 4= bodily pain, domain 5= vitality, domain 6= social function, domain 7= role emotional, domain 8= mental health. Total score for each domain are scaled 0 (minimum) to 100 (maximum), where higher scores represent better health status.
Measured: Baseline, Weeks 12 and 24
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Weeks 12, 24, 40 and 56: Last Observation Carried Forward (LOCF)
The SF-36 health survey is a self-administered questionnaire that measures each of the following 8 health domains: domain 1= general health, domain 2= physical function, domain 3= role physical, domain 4= bodily pain, domain 5= vitality, domain 6= social function, domain 7= role emotional, domain 8= mental health. Total score for each domain are scaled 0 (minimum) to 100 (maximum), where higher scores represent better health status.
Measured: Baseline, Weeks 12, 24, 40, and 56
Number of Participants Who Had Discontinued Study Due to Lack of Efficacy
Measured: Baseline up to Week 56
Time to Discontinuation Due to Lack of Efficacy
Time to discontinuation due to lack of efficacy was defined as the time interval from the date of study drug administration up to the date of discontinuation of participant from study due to lack of efficacy.
Measured: Baseline up to Week 56
Change From Baseline in Percent Work Time Missed Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Baseline Observation Carried Forward (BOCF)
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions (Q) are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent work time missed due to health problem: Q2/(Q2+Q4). The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.
Measured: Baseline, Week 24
Change From Baseline in Percent Work Time Missed Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Last Observation Carried Forward (LOCF)
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent work time missed due to health problem: Q2/(Q2+Q4). The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.
Measured: Baseline, Week 24 and 56
Change From Baseline in Percent Impairment While Working Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Baseline Observation Carried Forward (BOCF)
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent impairment while working due to health problem: Q5/10. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.
Measured: Baseline, Week 24
Change From Baseline in Percent Impairment While Working Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Last Observation Carried Forward (LOCF)
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent impairment while working due to health problem: Q5/10. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.
Measured: Baseline, Weeks 24 and 56
Change From Baseline in the Percent Overall Work Impairment Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): BOCF
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent overall work impairment due to health problem: Q2/(Q2+Q4)+[(1-Q2/(Q2+Q4))*(Q5/10)]. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.
Measured: Baseline, Week 24
Change From Baseline in the Percent Overall Work Impairment Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): LOCF
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent overall work impairment due to health problem: Q2/(Q2+Q4)+[(1-Q2/(Q2+Q4))*(Q5/10)]. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.
Measured: Baseline, Weeks 24 and 56
Change From Baseline in the Percent Activity Impairment Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP): Baseline Observation Carried Forward (BOCF)
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent activity impairment due to health problem: Q6/10. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.
Measured: Baseline, Week 24
Change From Baseline in the Percent Activity Impairment Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP): Last Observation Carried Forward (LOCF)
The WPAI assesses work productivity and impairment. It is a 6-item questionnaire used to assess the degree to which a specified health problem affected work productivity and regular activities over the past 7 days. The questions are: Q1 = currently employed. Q2 = hours missed due to health problems. Q3 = hours missed other reasons. Q4 = hours actually worked. Q5 = degree health affected productivity while working (0-10 scale). Q6 = degree health affected regular activities (0-10 scale). Subscale scores are calculated: Percent activity impairment due to health problem: Q6/10. The computed percentage range for each sub-scale is 0-100, where higher numbers indicate greater impairment and less productivity.
Measured: Baseline, Weeks 24, and 56
Percentage of Participants Who Used Rescue Medication: Observed Data
In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day for maximum of 3 days within a week could be taken as rescue medication. Percentage of participants with any use of rescue medication during each study interval were summarized.
Measured: Weeks 1-2, 3-4, 5-8, 9-12, 13-16, 17-24, 25-32, 33-40, 41-48 and 49-56
Percentage of Participants Who Used Rescue Medication: Last Observation Carried Forward (LOCF)
In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day for maximum of 3 days within a week could be taken as rescue medication. Percentage of participants with any use of rescue medication during each study interval were summarized.
Measured: Weeks 1-2, 3-4, 5-8, 9-12, 13-16, 17-24, 25-32, 33-40, 41-48 and 49-56
Amount of Rescue Medication Used
In case of inadequate pain relief for osteoarthritis, acetaminophen up to 4000 mg per day up to 3 days in a week could be taken as rescue medication. The total dosage of acetaminophen in mg used during the specified time intervals were summarized.
Measured: Weeks 1-2, 3-4, 5-8, 9-12, 13-16, 17-24, 25-32, 33-40, 41-48, and 49-56
Change From Baseline in Medial Minimum Joint Space Width of the Index Knee at Week 56
Measured: Baseline, Week 56
Change From Baseline in Minimum Joint Space Width of the Index Hip at Week 56
Measured: Baseline, Week 56
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to Week 64 that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.
Measured: Baseline up to Week 64
Change From Baseline in Neuropathy Impairment Score (NIS) at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Observed Data
The Neuropathy Impairment Score is the sum of scores over all 37 items from both the left and right side. The neurological impairment score assessed strength of groups of muscles of the head and neck, upper limbs and lower limbs, deep tendon reflexes and sensation (tactile, vibration, joint position sense, and pin prick) of index fingers and great toes through neurological examination. NIS calculated scoring muscle weakness (0=normal, 1=25% weak, 2=50% weak, 3=75% week, 3.25= move against gravity, 3.5=movement gravity eliminated, 3.75= muscle flicker no movement, 4=paralysis), scoring reflexes (0=normal, 1=reduced. 2=absent), scoring sensation (0=normal, 1=decreased, 2=absent). For NIS possible overall score (combined of both left and right sides of each domain), ranged from 0 (no impairment) to 244 (maximum impairment), higher scores indicated increased/more neuropathic deficits.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Change From Baseline in Neuropathy Impairment Score (NIS) at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)
The Neuropathy Impairment Score is the sum of scores over all 37 items from both the left and right side. The neurological impairment score assessed strength of groups of muscles of the head and neck, upper limbs and lower limbs, deep tendon reflexes and sensation (tactile, vibration, joint position sense, and pin prick) of index fingers and great toes through neurological examination. NIS calculated scoring muscle weakness (0=normal, 1=25% weak, 2=50% weak, 3=75% week, 3.25= move against gravity, 3.5=movement gravity eliminated, 3.75= muscle flicker no movement, 4=paralysis), scoring reflexes (0=normal, 1=reduced. 2=absent), scoring sensation (0=normal, 1=decreased, 2=absent). For NIS possible overall score (combined of both left and right sides of each domain), ranged from 0 (no impairment) to 244 (maximum impairment), higher scores indicated increased/more neuropathic deficits.
Measured: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56
Plasma Trough (Pre-dose) Concentration of Tanezumab
Measured: Predose on Day 1, Weeks 16, 24, 40, and 56
Number of Participants With Intravenous (IV) Doses of Study Medication
Number of participants are reported based on the maximum number of IV doses of either tanezumab or placebo received.
Measured: Baseline up to Week 48
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Dec 2008 (estimated)
- Study start12 Feb 2009
- Primary completion28 Oct 2010
- Study completion12 Jan 2011
Why it stopped: See termination reason in detailed description.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for OsteoarthritisStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 2,720 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00809354
- Sponsor's protocol ID
- A4091025
- Other IDs
- 2008-004815-37, OA CONTROLLED SAFETY STUDY, 2008
- Status last verified
- Jun 2021
- First submitted
- 16 Dec 2008
- Last updated
- 24 Jun 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- Individual data sharing
- Yes: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Publications
Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, West CR. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res. 2019 Mar 19;12:975-995. doi: 10.2147/JPR.S191297. eCollection 2019.
PubMed 30936738Hochberg MC, Tive LA, Abramson SB, Vignon E, Verburg KM, West CR, Smith MD, Hungerford DS. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. Arthritis Rheumatol. 2016 Feb;68(2):382-91. doi: 10.1002/art.39492.
PubMed 26554876Schnitzer TJ, Ekman EF, Spierings EL, Greenberg HS, Smith MD, Brown MT, West CR, Verburg KM. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis. 2015 Jun;74(6):1202-11. doi: 10.1136/annrheumdis-2013-204905. Epub 2014 Mar 13.
PubMed 24625625
Study at a glance
From the registry record, last updated by the sponsor on 24 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A PHASE 3, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY OF THE LONG-TERM ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ALONE OR IN COMBINATION WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) VERSUS NSAIDS ALONE IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP
- ClinicalTrials.gov ID
- NCT00809354
- Acronym / sponsor ID
- A4091025
- Conditions
- Osteoarthritis, Arthritis
- Keywords
- monoclonal antibody, nerve growth factor (NGF), anti-NGF, tanezumab, PF-04383119, RN624, osteoarthritis (OA)
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: See termination reason in detailed description.
- Enrolment
- 2,720 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- 12 Feb 2009 (actual)
- Primary completion
- 28 Oct 2010 (actual)
- Study completion
- 12 Jan 2011 (actual)
- First posted
- 17 Dec 2008 (estimated)
- Results
- Posted 24 Jun 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate the long-term analgesic efficacy and safety of tanezumab for patients with osteoarthritis (OA) of the knee or hip currently experiencing partial benefit from, and are tolerating, non-steroidal anti-inflammatory drug (NSAID) therapy.
Detailed description
This study was terminated on 28 October 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 5
| Arm | Type | Receives |
|---|---|---|
| IV Placebo + NSAID | Active comparator | Drug: NSAIDOral NSAID |
| Tanezumab 5 mg | Experimental | Biological: tanezumabIV tanezumab 5 mg every 8 weeks (through Week 48) |
| Tanezumab 10 mg | Experimental | Biological: tanezumabIV tanezumab 10 mg every 8 weeks (through Week 48) |
| Tanezumab 5 mg + NSAID | Experimental | Biological: tanezumab, Drug: NSAIDIV doses of tanezumab 5 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks |
| Tanezumab 10 mg + NSAID | Experimental | Biological: tanezumab, Drug: NSAIDIV doses of tanezumab 10 mg every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Osteoarthritis of the knee or hip according to ACR criteria with Kellgren-Lawrence x-ray grade equal to, or greater than, 2.
- Patients must be experiencing some benefit from their current stable dose regimen of oral NSAID therapy of either naproxen 500-1000 mg/day or celecoxib 200 mg/day (either 100 mg BID or 200 mg QD) and be tolerating their NSAID regimen.
- Pain level and function levels as required by the protocol at Screening and Baseline.
- Willing to discontinue all non-study pain medications for osteoarthritis except rescue medication (acetaminophen) and not use prohibited pain medications throughout the duration of the study except as permitted per protocol.
- Willing and able to comply with lifestyle guidelines, scheduled visits, treatment plan, laboratory tests and other study procedures.
Key exclusion criteria (9 listed)
- Pregnant women.
- BMI greater than 39.
- Fibromyalgia, regional pain caused by lumbar or cervical compression with radiculopathy or other moderate to sever pain that may confound assessments or self-evaluation of the pain associated with OA.
- Signs and symptoms of clinically significant cardiac disease with 6 months prior to screening.
- Diagnosis of TIA within 6 months prior to screening or diagnosis of stroke with residual deficits that would preclude completion of required study activities.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NSAIDIV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks | Drug | IV Placebo + NSAID |
| tanezumabIV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56 | Biological | Tanezumab 5 mg |
| tanezumabIV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56 | Biological | Tanezumab 10 mg |
| tanezumabIV tanezumab 5 mg every 8 weeks (through Week 48) | Biological | Tanezumab 5 mg + NSAID |
| NSAIDOral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks | Drug | Tanezumab 5 mg + NSAID |
| tanezumabIV tanezumab 10 mg every 8 weeks (through Week 48) | Biological | Tanezumab 10 mg + NSAID |
| NSAIDOral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks | Drug | Tanezumab 10 mg + NSAID |
Primary outcome
Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16
Time frame: Baseline, Week 16
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip). The WOMAC pain subscale was a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 5 individual questions scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain. Total score range for WOMAC pain subscale score was 0 (no pain) to 10 (worst possible pain), where higher scores indicated higher pain.
Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16
Time frame: Baseline, Week 16
WOMAC: self-administered, disease-specific 24-item questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis of index joint (knee or hip).The WOMAC physical function subscale was comprised of 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS of 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Total score range for WOMAC physical function subscale score was 0 (minimum difficulty) to 10 (maximum difficulty), where higher scores indicated worse physical function. Physical function refers to participant's ability to move around and perform usual activities of daily living.
Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Week 16
Time frame: Baseline, Week 16
Patient global assessment of osteoarthritis was assessed by asking a question from participants: "Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?" Participants responded by using a 5-point likert scale ranging from 1=very good (asymptomatic and no limitation of normal activities, 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher scores indicating worse condition.
44 secondary outcomes
Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)
Time frame: Baseline, Weeks 2, 4, 8, 12, and 24
Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)
Time frame: Baseline, Weeks 2, 4, 8, 12, and 24
Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)
Time frame: Baseline, Weeks 2, 4, 8, 12, 24, 32, 40, 48, and 56
Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12 and 24: Baseline Observation Carried Forward (BOCF)
Time frame: Baseline, Weeks 2, 4, 8, 12, and 24
Change From Baseline in the Patient Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response: Baseline Observation Carried Forward (BOCF)
Time frame: Weeks 2, 4, 8, 12, 16, and 24
Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response: Last Observation Carried Forward (LOCF)
Time frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Percentage of Participants With at Least 30 Percent (%), 50%, 70% and 90% Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score From Baseline at Weeks 2, 4, 8, 12, 16, and 24: BOCF
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, and 24
Percentage of Participants With at Least 30%, 50%, 70% and 90% Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF)
Time frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Baseline Observation Carried Forward (BOCF)
Time frame: Baseline, Week 16
Number of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score: Last Observation Carried Forward (LOCF)
Time frame: Baseline, Week 16
Percentage of Participants With Improvement of At Least 2 Points in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, 16, and 24: Baseline Observation Carried Forward (BOCF)
Time frame: Weeks 2, 4, 8, 12, 16, and 24
Percentage of Participants With Improvement of Atleast 2 Points in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56: Last Observation Carried Forward (LOCF)
Time frame: Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, and 24
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, and 24
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, and 24
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Down Stairs at Weeks 2, 4, 8, 12, 16 and 24: Baseline Observation Carried Forward (BOCF)
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, and 24
Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Down Stairs at Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48 and 56: Last Observation Carried Forward (LOCF)
Time frame: Baseline, Weeks 2, 4, 8, 12, 16, 24, 32, 40, 48, and 56
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Week 12 and 24: Baseline Observation Carried Forward (BOCF)
Time frame: Baseline, Weeks 12 and 24
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) at Weeks 12, 24, 40 and 56: Last Observation Carried Forward (LOCF)
Time frame: Baseline, Weeks 12, 24, 40, and 56
Number of Participants Who Had Discontinued Study Due to Lack of Efficacy
Time frame: Baseline up to Week 56
Time to Discontinuation Due to Lack of Efficacy
Time frame: Baseline up to Week 56
Change From Baseline in Percent Work Time Missed Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Baseline Observation Carried Forward (BOCF)
Time frame: Baseline, Week 24
Change From Baseline in Percent Work Time Missed Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Last Observation Carried Forward (LOCF)
Time frame: Baseline, Week 24 and 56
Change From Baseline in Percent Impairment While Working Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Baseline Observation Carried Forward (BOCF)
Time frame: Baseline, Week 24
Change From Baseline in Percent Impairment While Working Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): Last Observation Carried Forward (LOCF)
Time frame: Baseline, Weeks 24 and 56
Change From Baseline in the Percent Overall Work Impairment Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): BOCF
Time frame: Baseline, Week 24
Change From Baseline in the Percent Overall Work Impairment Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire- Specific Health Problem (WPAI-SHP): LOCF
Time frame: Baseline, Weeks 24 and 56
Change From Baseline in the Percent Activity Impairment Due to Osteoarthritis at Week 24 Assessed Using Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP): Baseline Observation Carried Forward (BOCF)
Time frame: Baseline, Week 24
Change From Baseline in the Percent Activity Impairment Due to Osteoarthritis at Week 24 and 56 Assessed Using Work Productivity and Activity Impairment Questionnaire - Specific Health Problem (WPAI-SHP): Last Observation Carried Forward (LOCF)
Time frame: Baseline, Weeks 24, and 56
Percentage of Participants Who Used Rescue Medication: Observed Data
Time frame: Weeks 1-2, 3-4, 5-8, 9-12, 13-16, 17-24, 25-32, 33-40, 41-48 and 49-56
Percentage of Participants Who Used Rescue Medication: Last Observation Carried Forward (LOCF)
Time frame: Weeks 1-2, 3-4, 5-8, 9-12, 13-16, 17-24, 25-32, 33-40, 41-48 and 49-56
Amount of Rescue Medication Used
Time frame: Weeks 1-2, 3-4, 5-8, 9-12, 13-16, 17-24, 25-32, 33-40, 41-48, and 49-56
Change From Baseline in Medial Minimum Joint Space Width of the Index Knee at Week 56
Time frame: Baseline, Week 56
Change From Baseline in Minimum Joint Space Width of the Index Hip at Week 56
Time frame: Baseline, Week 56
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Baseline up to Week 64
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jun 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 30936738Tive L, Bello AE, Radin D, Schnitzer TJ, Nguyen H, Brown MT, West CR. Pooled analysis of tanezumab efficacy and safety with subgroup analyses of phase III clinical trials in patients with osteoarthritis pain of the knee or hip. J Pain Res. 2019 Mar 19;12:975-995. doi: 10.2147/JPR.S191297. eCollection 2019.
- Derived from this study: PubMed 26554876Hochberg MC, Tive LA, Abramson SB, Vignon E, Verburg KM, West CR, Smith MD, Hungerford DS. When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. Arthritis Rheumatol. 2016 Feb;68(2):382-91. doi: 10.1002/art.39492.
- Derived from this study: PubMed 24625625Schnitzer TJ, Ekman EF, Spierings EL, Greenberg HS, Smith MD, Brown MT, West CR, Verburg KM. Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis pain. Ann Rheum Dis. 2015 Jun;74(6):1202-11. doi: 10.1136/annrheumdis-2013-204905. Epub 2014 Mar 13.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Related trials for Osteoarthritis
Not yet recruiting
Holistic Healing for Knee Osteoarthritis
Knee Osteoarthritis (Knee OA)
Active, not recruiting
Effectiveness of Therapeutic Exercises on Spinopelvic Mobility
Osteoarthritis (OA) of the Hip
Recruiting
Effect of Anti-inflammatory Diet in Osteoarthritis
Osteoarthritis, Knee
Active, not recruitingPhase 2/3
Single vs Triple Hyaluronic Acid in Knee Osteoarthritis
Osteoarthritis, Knee
Not yet recruiting
The Feasibility of a Virtual/Home-based OA Treatment Program in Older Adults With OA and Multimorbidity
Osteoarthritis of the Knee
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
333 sites in 12 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing NSAID and tanezumab in people with Osteoarthritis and Arthritis, run by Pfizer at 333 sites in 12 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 24 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 333 sites in United States, South Africa, Canada, Spain, India and 7 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 24 Jun 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16 (time frame: Baseline, Week 16). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00809354, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2021.